Search

Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*star for Targeted Cancer Therapies

Corporate Compliance Program

Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies

Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies

BI Cares Financial Contributions Program: Strengthening Communities

Jardiance® (empagliflozin) Shows Reduction in CV Risk & Death | Boehringer Ingelheim US

BI & Eli Lilly & Co.’s JARDIANCE reduced risk of CV death, non-fatal heart attack or non-fatal stroke by 14%. View ISI, PI and Med Guide.

The Burdens of Schizophrenia

It can be hard for people living without schizophrenia to realize its burdens. Understanding these challenges can provide insights to help patients in need.

live_well_with_gpp_infographic.pdf

Funding Opportunities

World Water Day 2019 | Boehringer Ingelheim US

Click here to find out more on the steps Boehringer Ingelheim are taking on World Water Day 2019 to support animal shelters in Mexico City.

Our People, Our Culture

Ridgefield, CT | BI Facilities

BI was established in Connecticut in 1971 and broke ground on September 1st, 1989 in Ridgefield. This site is home to the U.S. HQ of Boehringer Ingelheim

Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio

Learning and development

We help people grow professionally by maximizing our talent and giving them room to evolve within the company.

Biosimilars

MERIAL: RECOMBITEK® Oral Bordetella Vaccine | Boehringer Ingelheim US

MERIAL, now part of Boehringer Ingelheim, grows canine vaccine portfolio with the introduction of the RECOMBITEK® Oral Bordetella vaccine.

Our partners Bioveta

Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership

Statement by Boehringer Ingelheim on selection of Jardiance® (empagliflozin) by the Centers for Medicare and Medicaid Services (CMS) Drug Price Negotiation Program

BI & Gubra Join Forces to Identify Peptides | Boehringer Ingelheim US

BI & Gubra announce research & licensing agreement focused on the identification & validation of targets & peptide compounds for the treatment of obesity.

Life Forward

In everything we do we can shape and influence the future for the better: Learn more about “Life forward” and how our innovations improve lives.

Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration

Technologies

We are expanding our global network of technology partners. Learn more about partnering with us.

Mental Health and the Value of Connection

New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies

Our Grass Roots Innovation Program

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers